Should Investors Be Concerned About This Pharmaceutical Giant's Latest Clinical Trial?The Motley Fool • 01/06/26
Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026?Zacks Investment Research • 01/06/26
Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting CostBenzinga • 01/05/26
China Market Unsettled, But Novo Nordisk's Oral Wegovy May Keep Revenue On TrackSeeking Alpha • 01/05/26
Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.Market Watch • 01/05/26
Novo Nordisk Launches Wegovy™ Pill, Expanding Patient Choice and Access With knownwell as a Recognized NovoCare® ProviderBusiness Wire • 01/05/26
Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?Zacks Investment Research • 01/05/26
Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across AmericaPRNewsWire • 01/05/26
Novo Nordisk to sell Wegovy pill to US self-pay patients starting at $149 per monthReuters • 01/05/26
Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in ChinaZacks Investment Research • 01/02/26
Novo Nordisk enters 2026 on the defense as it faces a ‘must-win' battle in the U.S. marketCNBC • 01/01/26
Novo Nordisk A/S: China's Supreme People's Court delivers a positive ruling on the semaglutide compound patentGlobeNewsWire • 12/31/25
Novo Nordisk's 'long game' on weight loss drugs sparks hope in science, but the Street is impatientCNBC • 12/30/25